SYNCAR-001

N/A

Report date: 2024/09/05 09:09:26

Base Information

Drug NameSYNCAR-001
Drug Alias NameOrthogonal IL-2 receptor-modified CD-19 targeted CAR-T cell therapy(Synthekine)SYNCAR-001
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionImmunostimulantsT lymphocyte replacementsImmunologic cytotoxicity +[4] 
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsScleroderma, SystemicLupus Erythematosus, SystemicLupus Nephritis +[10] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesSynthekine Inc
China Registration ClassN/A

Develop Information

Active CompaniesSynthekine Inc
Inactive CompaniesN/A
Active IndicationsScleroderma, SystemicLupus Erythematosus, SystemicLupus Nephritis +[10] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A